Business
Odyssey Therapeutics Appoints Pharmaceutical Leader Nia Tatsis, Ph.D., to Its Board of Directors
BOSTON, October 09, 2025--Odyssey announces appointment of Nia Tatsis, Ph.D., EVP of Vertex Pharmaceuticals, to its Board of Directors.
About this update from Vertex Pharmaceuticals Incorporated
[{"type":"image","alt":"Nia Tatsis, Ph.D., Odyssey Therapeutics Board of Directors","displaySize":"","headline":null,"caption":"Nia Tatsis, Ph.D., Odyssey Therapeutics Board of Directors","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":421,"height":480,"url":"https://media.zenfs.com/en/business-wire.com/c91f512e5cf4670be95c5d05ecc54dc4"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/9mA1aULRMz7rMngn7bKcwg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTgwNDtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/c91f512e5cf4670be95c5d05ecc54dc4","width":421,"height":480}},"lazy":false},{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":1200,"height":322,"url":"https://media.zenfs.com/en/business-wire.com/97d925acc2cf39bd6582c5dd541fbe2b"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/ZtuA1w6k9e4RlC52jQHjIg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTI1ODtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/97d925acc2cf39bd6582c5dd541fbe2b","width":960,"height":258},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/QQTo7UPyDasyLpBPzO21BA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTI0MDA7aD02NDQ7Y2Y9d2VicA--/https://media.zenfs.com/en/business-wire.com/97d925acc2cf39bd6582c5dd541fbe2b","width":1200,"height":322}}},{"type":"text","content":"BOSTON, October 09, 2025--(BUSINESS WIRE)--Odyssey Therapeutics, Inc., a clinical-stage biopharmaceutical company seeking to transform the standard of care for patients suffering from autoimmune and inflammatory diseases by developing medicines that precisely target disease pathology, today announced the appointment of Nia Tatsis, Ph.D., to its board. Dr. Tatsis is currently Executive Vice President and Chief Regulatory and Quality Officer of Vertex Pharmaceuticals and brings more than 20 years of experience in regulatory affairs and quality assurance.","length":558,"tagName":"p"},{"type":"text","content":""I am thrilled to welcome Nia to the board of Odyssey as we advance our RIPK2 scaffolding inhibitor and broader pipeline through clinical development," said Gary D. Glick, Ph.D., Founder and CEO of Odyssey Therapeutics. "Nia’s deep expertise spanning clinical development, regulatory, manufacturing, and commercialization will be invaluable as we continue on our mission of delivering tra...